Immunomedics Inc (IMMU) Stock Price, Quote, News and Overview
NASDAQ:IMMU - Nasdaq -
IMMU Quote, Performance and Key Statistics
87.86
+0.04 (+0.05%)
The current stock price of IMMU is 87.86 null. In the past month the price increased by 3%. In the past year, price increased by 442.35%.
About IMMU
Company Profile
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or `naked` form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.
Company Info
Immunomedics Inc
300 AMERICAN RD
MORRIS PLAINS NJ 07950
CEO: Usama Malik
Phone: 973-605-8200
Immunomedics Inc / IMMU FAQ
What is the stock price of Immunomedics Inc today?
The current stock price of IMMU is 87.86 null. The price increased by 0.05% in the last trading session.
What is the ticker symbol for Immunomedics Inc stock?
The exchange symbol of Immunomedics Inc is IMMU and it is listed on the Nasdaq exchange.
On which exchange is IMMU stock listed?
IMMU stock is listed on the Nasdaq exchange.
What is Immunomedics Inc worth?
Immunomedics Inc (IMMU) has a market capitalization of 20.31B null. This makes IMMU a Large Cap stock.
What are the support and resistance levels for Immunomedics Inc (IMMU) stock?
Immunomedics Inc (IMMU) has a support level at 87.21 and a resistance level at 87.87. Check the full technical report for a detailed analysis of IMMU support and resistance levels.
Should I buy Immunomedics Inc (IMMU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMMU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMMU, evaluating the profitability, health, valuation and growth aspects
- Immunomedics Inc (IMMU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Immunomedics Inc (IMMU) Sales and EPS estimates to see what analysts future expectations are.
- Immunomedics Inc (IMMU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Immunomedics Inc (IMMU) Insider and Institutional Ownership to learn about the owners and their transactions.
- Immunomedics Inc (IMMU) Stock Chart to make your own analysis
- Immunomedics Inc (IMMU) Latest news and press-releases to stay up to date.
Does Immunomedics Inc (IMMU) stock pay dividends?
IMMU does not pay a dividend.
What is the Price/Earnings (PE) ratio of Immunomedics Inc (IMMU)?
Immunomedics Inc (IMMU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.73).
IMMU Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMMU. When comparing the yearly performance of all stocks, IMMU is one of the better performing stocks in the market, outperforming 99.45% of all stocks.
IMMU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMU. IMMU has a great financial health rating, but its profitability evaluates not so good.
IMMU Financial Highlights
Over the last trailing twelve months IMMU reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS decreased by -40.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1760.55% | ||
| ROA | -32.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
IMMU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to IMMU. The Buy consensus is the average rating of analysts ratings from 7 analysts.